Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8719805 | The Journal of Emergency Medicine | 2017 | 18 Pages |
Abstract
While findings of decreased time to symptom resolution or a cessation in symptom progression have been reported with each of these therapies, additional data showing clinically relevant implications, such as reduced intensive care unit length of stay or avoidance of mechanical ventilation, are warranted, especially when taking cost into consideration. FFP has limited evidence demonstrating a benefit for treatment of ACEI-induced angioedema without consistent dosing strategies. However, given its wide availability and low potential for adverse reactions, FFP therapy may be reasonable. Of the novel agents traditionally used for hereditary angioedema, icatibant has the highest level of evidence and has been reported to be successful in limiting the progression of angioedema.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Emergency Medicine
Authors
Heidi M. PharmD, BCPS, Bryant B. PharmD, BCPS, Jessica V. PharmD, BCPS, Megan A. PharmD, BCPS, BCCCP,